(0.14%) 5 302.75 points
(-0.05%) 38 771 points
(0.37%) 18 661 points
(0.32%) $77.24
(3.94%) $2.69
(0.03%) $2 346.40
(-0.23%) $30.37
(-0.53%) $1 036.50
(0.16%) $0.923
(0.12%) $10.50
(0.19%) $0.787
(-1.06%) $89.48
Live Chart Being Loaded With Signals
Statera BioPharma, Inc., a clinical-stage biopharmaceutical company, develops novel immunotherapies targeting autoimmune, neutropenia/anemia, emerging viruses, and cancers based on a proprietary platform designed to rebalance the body's immune system and restore homeostasis...
Stats | |
---|---|
Today's Volume | 307.00 |
Average Volume | 7 540.00 |
Market Cap | 42 850.00 |
EPS | $0 ( 2024-05-17 ) |
Next earnings date | ( $0 ) 2024-06-14 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | 0 |
ATR14 | $0 (0.00%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2022-02-22 | Chandrasekhar Satishchandran | Buy | 0 | |
2021-09-09 | Saluck Randy S. | Buy | 60 000 | Common Stock, par value $0.005 per share |
2021-09-09 | Barbarick Steve K | Buy | 60 000 | Common Stock, par value $0.005 per share |
2021-09-09 | Verny Lea | Buy | 60 000 | Common Stock, par value $0.005 per share |
2021-09-28 | Markvicka Taunia | Buy | 100 000 | Common Stock, par value $0.005 per share |
INSIDER POWER |
---|
0.00 |
Last 70 transactions |
Buy: 2 421 695 | Sell: 3 004 967 |
Statera Biopharma, Inc. Correlation
10 Most Positive Correlations |
---|
10 Most Negative Correlations | |
---|---|
EVOK | -0.848 |
GLBS | -0.846 |
VRM | -0.845 |
INVZ | -0.838 |
SPI | -0.836 |
NWFL | -0.832 |
WALD | -0.83 |
IMMX | -0.829 |
VVOS | -0.828 |
MNSB | -0.827 |
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Statera Biopharma, Inc. Financials
Annual | 2021 |
Revenue: | $1.49M |
Gross Profit: | $998 722 (67.16 %) |
EPS: | $-2.90 |
FY | 2021 |
Revenue: | $1.49M |
Gross Profit: | $998 722 (67.16 %) |
EPS: | $-2.90 |
FY | 2020 |
Revenue: | $0.00 |
Gross Profit: | $0.00 (0.00 %) |
EPS: | $-0.471 |
FY | 2019 |
Revenue: | $0.00 |
Gross Profit: | $0.00 (0.00 %) |
EPS: | $-0.126 |
Financial Reports:
No articles found.
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Statera Biopharma, Inc.
Statera BioPharma, Inc., a clinical-stage biopharmaceutical company, develops novel immunotherapies targeting autoimmune, neutropenia/anemia, emerging viruses, and cancers based on a proprietary platform designed to rebalance the body's immune system and restore homeostasis. The company is developing therapies designed to directly elicit within patients a response of antigen-specific killer T-cells and antibodies, thereby activating essential immune defenses against autoimmune, inflammatory, infectious diseases, and cancers. It has clinical programs for Crohn's disease (STAT-201), hematology (Entolimod), pancreatic cancer (STAT-401), and COVID-19 (STAT-205), as well as expanding into fibromyalgia and multiple sclerosis. The company was formerly known as Cytocom, Inc. and changed its name to Statera Biopharma, Inc. in September 2021. The company is based in Fort Collins, Colorado.
About Live Signals
The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.
The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators